This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other porphyrias (acute intermittent porphyria / hereditary coproporphyria)Other Porphyrias (Acute Intermittent Porphyria / Hereditary Coproporphyria)

ItemDetails
A. Classification codesICD-10: E80.2 (other porphyrias) | Special Copayment Reduction: V118
B. SynonymsAcute intermittent (hepatic) porphyria (AIP), hereditary coproporphyria (HCP), porphyria NOS, Acute Hepatic Porphyria (AHP)
C. Adult onsetLikelihood of first onset in adulthood high — acute porphyria typically first presents as an acute attack after puberty, especially in women in their 20s–40s, triggered by factors such as hormonal changes, drugs, or food, and a great many carriers are asymptomatic until adulthood.
1. HistoryFirst reported in the late 19th century; AIP defined by Waldenstrom in 1937; HMBS and CPOX genes identified
2. CausesAIP: HMBS gene variants → hydroxymethylbilane synthase deficiency; HCP: CPOX gene variants → coproporphyrinogen oxidase deficiency
3. GeneticsAutosomal dominant; AIP-HMBS (11q23.3), HCP-CPOX (3q12); low penetrance (10–20%)
4. EpidemiologyAIP: about 1–2 per 100,000 (Europe); female predominance; HCP: rarer than AIP, about 1–2 per 1,000,000
5. PathophysiologyExcess accumulation of heme synthesis intermediates (ALA, PBG, coproporphyrinogen) → neurotoxicity → acute neurovisceral attacks
6. SymptomsAcute attacks: abdominal pain (85–95%), nausea and vomiting, constipation, hypertension, tachycardia, hyponatremia, peripheral neuropathy; HCP: additional photosensitive skin lesions
7. SignsAbdominal tenderness (without surgical findings), autonomic instability, ascending paralysis (porphyric crisis), red to brown urine
8. ScreeningQualitative urine porphobilinogen (PBG) test during acute attacks (Watson-Schwartz/Hoesch test)
9. DiagnosisQuantitative analysis of urine, plasma, and fecal porphyrins; HMBS/CPOX enzyme activity; molecular genetic testing
10. TreatmentAcute attacks: intravenous hemin (Heme arginate), givosiran (siRNA); high-carbohydrate therapy; removal of triggering factors
11. PrognosisMost recover with appropriate treatment; patients with recurrent attacks have increased risk of chronic nephropathy and hepatocellular carcinoma
12. PreventionAvoidance of triggering drugs, alcohol, fasting, and stress; prophylactic givosiran; genetic counseling for carrier family members
13. ReferencesList of key PMIDs and DOIs

1. History

The history of porphyria dates back to the late 19th century. In 1871 Felix Hoppe-Seyler first isolated porphyrin from hemoglobin, and in 1889 B.J. Stokvis first described a case of acute porphyria. The clinical definition of Acute Intermittent Porphyria (AIP) was established in 1937 by Jan Waldenstrom of Sweden, who systematically organized the triad of abdominal pain, neurological symptoms, and red urine. In 1954 Rimington and Meyer discovered excess urinary porphobilinogen (PBG) excretion in AIP, and it was subsequently shown that enzyme defects in the heme synthesis pathway are the mechanism of porphyria. Hereditary Coproporphyria (HCP) was described as a separate clinical entity by Berger and Goldberg in 1955. In the 1990s, the causative gene of AIP, HMBS (Hydroxymethylbilane synthase, formerly: Porphobilinogen deaminase gene), was identified at 11q23.3, and that of HCP, CPOX (Coproporphyrinogen oxidase), at 3q12. In 2019, givosiran (Givlaari®), which uses an RNA interference mechanism, received FDA approval and brought innovation to the treatment of acute hepatic porphyria.

2. Causes

Acute intermittent porphyria (AIP): variants in the HMBS gene (11q23.3) reduce the activity of hydroxymethylbilane synthase (former name: Porphobilinogen deaminase) to about 50% of normal. In the heme synthesis pathway, this enzyme links 4 PBG molecules to produce hydroxymethylbilane. Because enzyme activity is halved, ALA (delta-aminolevulinic acid) and PBG accumulate in excess upon stimuli that induce heme synthesis (drugs, hormonal changes, fasting, etc.).

Hereditary coproporphyria (HCP): variants in the CPOX gene (3q12) reduce coproporphyrinogen oxidase activity by about 50%. This enzyme converts coproporphyrinogen III to protoporphyrinogen IX at the mitochondrial step of the heme synthesis pathway. When the enzyme is deficient, coproporphyrinogen III and its oxidation product coproporphyrin III accumulate in excess in the liver, blood, urine, and feces. Unlike AIP, cutaneous phototoxicity of coproporphyrin can occur, so photosensitive skin lesions accompany it.

3. Genetics

Acute hepatic porphyrias (both AIP and HCP) follow an autosomal dominant mode of inheritance. That is, a variant in only one allele is enough to reduce enzyme activity and create a predisposition to disease. However, actual clinical penetrance is very low, and only 10–20% of variant carriers experience one or more acute attacks in their lifetime. The remaining 80–90% remain asymptomatic carriers for life. The AIP causative gene HMBS is located at 11q23.3 and the HCP causative gene CPOX at 3q12.1. More than 200 pathogenic variants have been reported in each gene, and genotype–phenotype correlation is incomplete. The reason for higher expression in women is that changes in sex hormones (especially progesterone) induce expression of ALAS1 (ALA synthase 1). HCP occurs more rarely than AIP, and its clinical presentation is often milder.

4. General epidemiology

The estimated prevalence of acute intermittent porphyria (AIP) in Europe is about 1–2 per 100,000, but high frequencies reaching about 10 per 100,000 are reported in some areas such as northern Sweden and Ireland due to founder effects. Worldwide, symptomatic patients are estimated at about 10,000–20,000. Including asymptomatic carriers, the actual number of variant carriers is much greater. Symptom onset is concentrated after puberty, especially in the 20s–40s, and about 85% of symptomatic patients are women. It also occurs in men, but at a lower frequency. Hereditary coproporphyria (HCP) is much rarer than AIP, estimated at about 1–2 per 1,000,000. Accurate epidemiological data for Asia, including Korea, are limited, and the number of registered patients in Korea is small. Long-term observational studies of acute porphyria patients have reported a higher risk of chronic nephropathy and Hepatocellular carcinoma (HCC) than in the general population.

5. Pathophysiology

The core pathophysiology of acute porphyria is excess accumulation of intermediates due to an enzyme defect in the hepatic heme synthesis pathway. Normally, the heme end product suppresses expression of ALAS1 (ALA synthase, the rate-limiting enzyme of the heme synthesis pathway) in the liver by negative feedback, keeping the pathway stable. In AIP/HCP patients, when triggering factors such as drugs, steroid hormones, fasting, infection, or stress occur, ALAS1 expression is excessively induced. When the pathway is blocked by HMBS (AIP) or CPOX (HCP) deficiency, the upstream intermediates ALA (5-aminolevulinic acid) and PBG (porphobilinogen) are produced in large amounts in the liver and excreted into the blood and urine. ALA is a neurotoxic substance that damages the autonomic, peripheral, and central nervous systems through GABA receptor antagonism and induction of oxidative stress. This neurotoxicity explains the clinical picture of acute attacks, such as abdominal pain, peripheral neuropathy, psychiatric symptoms, and autonomic instability. In HCP, coproporphyrin additionally accumulates in the skin, causing sunlight-induced skin damage.

6. Symptoms

Acute attacks: severe abdominal pain of sudden onset occurs in 85–95% of patients; it is located mainly in the lower abdomen but may also radiate to the whole abdomen, chest, and back. Nausea, vomiting, and constipation (rarely diarrhea) accompany it. Autonomic dysfunction causes tachycardia, hypertension, abnormal sweating, and urinary retention. Hyponatremia (SIADH pattern) is common and, when severe, causes seizures. When peripheral neuropathy (mainly motor, ascending) develops, it can lead to limb weakness and respiratory muscle paralysis, requiring intensive care. Psychiatric symptoms (anxiety, agitation, confusion, hallucinations) also occur. Attacks last days to weeks, and recovery follows removal of triggering factors and appropriate treatment.

Additional symptoms of HCP: photosensitive skin lesions (blisters, skin fragility, and pigmentation in sun-exposed areas) are absent in AIP but observed in HCP (and variegate porphyria, VP). Skin lesions may appear simultaneously with or separately from acute neurovisceral symptoms.

7. Signs

On physical examination during an acute attack, palpation of the abdomen reveals tenderness, but there are often no signs of peritoneal irritation (abdominal rigidity, rebound tenderness), so differentiation from organic intra-abdominal disease is important. Decreased bowel sounds (ileus pattern) may occur. Autonomic instability produces tachycardia (100–150 beats per minute) and elevated blood pressure. When peripheral neuropathy has progressed, decreased or absent deep tendon reflexes and muscle weakness (especially proximal) are found. With severe neurological involvement, respiratory muscle paralysis causes reduced chest movement and decreased oxygen saturation. A change in urine color to red to brown (red urine) is a specific sign due to PBG/porphyrin excretion. Blood tests commonly show hyponatremia, hypomagnesemia, and elevated liver enzymes. On skin examination of HCP patients, blisters, erosions, scars, and pigmentation are observed in sun-exposed areas.

8. Screening

In patients with a suspected acute attack, the first screening test is a qualitative urine PBG test (Watson-Schwartz test or Hoesch test). This test can be performed immediately on fresh urine and is strongly positive in almost all AIP/HCP patients during an attack. A positive result must be confirmed by quantitative urine porphyrin/PBG measurement. Fractionation analysis of urine, plasma, and fecal porphyrins is essential for differentiating the type of porphyria. AIP: markedly elevated urine ALA and PBG; plasma and fecal porphyrins normal or mildly elevated. HCP: elevated urine ALA and PBG (milder than in AIP); markedly elevated fecal coproporphyrin III; elevated plasma porphyrins. Even between symptomatic episodes (in remission), AIP patients often have persistently elevated urine ALA/PBG, so testing is possible. In HCP, urine porphyrins may normalize between attacks, so fecal porphyrin analysis is important.

9. Diagnosis

Biochemical tests: ALA, PBG, and porphyrins are measured quantitatively in a 24-hour urine collection or a random urine sample (creatinine-corrected). In AIP, ALA and PBG are markedly elevated, and in HCP, coproporphyrin III is markedly increased in feces. The plasma porphyrin fluorescence peak (AIP: none; HCP: 620–625 nm) helps in differentiation.

Enzyme activity measurement: AIP: measurement of HMBS activity in erythrocytes or fibroblasts (reduced to about 50% of normal). HCP: measurement of CPOX activity in lymphocytes or fibroblasts. Enzyme measurement has lower clinical utility than genetic testing, but is used to support the diagnosis.

Molecular genetic testing: pathogenic variants are identified by sequencing and deletion/duplication analysis of the HMBS (AIP) or CPOX (HCP) gene. After the familial variant is identified, it is used for carrier screening and prenatal diagnosis. NGS testing with an acute porphyria clinical panel (AHP Panel) is useful for differentiating multiple types simultaneously.

10. Treatment

Treatment of acute attacks: immediate removal of triggering factors (discontinuing the causative drug, providing sufficient carbohydrates, treating infection) is the first step. Intravenous hemin (Heme arginate, Normosang®) is the standard treatment for acute attacks; it suppresses ALAS1 expression by negative feedback and reduces ALA/PBG production. The dose is 3–4 mg/kg given intravenously for 4 days. Opioid analgesics (morphine class) are used for pain control, and antiemetics such as ondansetron are given for nausea and vomiting. For seizures, gabapentin or levetiracetam is recommended (valproate/barbiturates are contraindicated due to the risk of worsening porphyria). Active correction of hyponatremia and use of beta-blockers to control heart rate and blood pressure are necessary.

Preventive treatment: Givosiran (Givlaari®, Alnylam Pharmaceuticals) degrades ALAS1 mRNA in the liver through an siRNA mechanism, fundamentally suppressing ALA/PBG production. It is given by subcutaneous injection once a month, and a breakthrough effect of reducing attack frequency by 70–80% in patients with recurrent acute attacks was confirmed in a Phase III clinical trial. It received FDA approval in 2019 and EMA approval in 2020. A high-carbohydrate diet (200 g or more per week), adequate nutrition during pregnancy, and management of a list of triggering drugs are important.

11. Prognosis

Most acute attacks resolve with appropriate treatment. The frequency and severity of attacks vary greatly from patient to patient. Some patients experience only 1–2 attacks in their lifetime, whereas in patients with chronic recurrent attacks (4 or more per year), quality of life is markedly reduced. When peripheral neuropathy has progressed severely, recovery takes several months, and in some cases recovery is incomplete. Several cohort studies have reported that, in the long term, patients with recurrent attacks have a significantly higher risk of chronic nephropathy (hepatic porphyria–related kidney disease) and hepatocellular carcinoma (HCC) than the general population. Accordingly, a liver cancer surveillance program including liver ultrasound is recommended for AIP patients aged 35 or older. With the introduction of preventive treatments such as givosiran, deaths and complications related to acute attacks have recently been decreasing.

12. Prevention

Management of triggering factors is the key to preventing acute porphyria. Patients should be familiar with the list of drugs to avoid in porphyria (see the porphyria drug database NAPOS or www.drugs-porphyria.org) and safety should be confirmed before every new prescription. In particular, barbiturates, sulfonamides, rifampin, ergotamine, and some antiepileptic drugs (carbamazepine, valproate) are contraindicated. Excessive alcohol intake, prolonged fasting or a low-carbohydrate diet, smoking, and excessive stress should be avoided. In patients with premenstrual attacks associated with the progesterone cycle, hormonal suppression with GnRH agonists is effective. Prophylactic givosiran is strongly recommended for patients with chronic recurrent attacks (4 or more per year). Family members identified as carriers are provided with genetic counseling, education on the drug list, and education on early recognition of symptoms. Diagnosed patients should always carry a medical alert card or bracelet.

13. References

  1. Waldenstrom J. Studies on the incidence and heredity of acute porphyria in Sweden. Acta Genet Stat Med. 1957;6(1):122-131. PMID: 13413095
  2. Anderson KE, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005;142(6):439-450. PMID: 15767622
  3. Bissell DM, et al. Porphyria. N Engl J Med. 2017;377(9):862-872. PMID: 28854088
  4. Stein PE, et al. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. Gastroenterology. 2023;165(2):290-300. PMID: 37179100
  5. Balwani M, et al. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. N Engl J Med. 2020;382(24):2289-2301. PMID: 32521132
  6. Gouya L, et al. EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks. Hepatology. 2020;71(5):1546-1558. PMID: 31880328
  7. Harper P, et al. Givosiran: a targeted treatment for acute intermittent porphyria. Hematology Am Soc Hematol Educ Program. 2024;2024(1):426-434. DOI: 10.1182/hematology.2024000615
  8. Schmitt C, et al. Acute hepatic porphyrias: current challenges and future priorities. Lancet Gastroenterol Hepatol. 2019;4(12):956-972. PMID: 31588020
  9. Elder GH, et al. The acute porphyrias. Lancet. 1997;349(9065):1613-1617. PMID: 9174565
  10. Puy H, Gouya L, Deybach JC. Porphyrias. Lancet. 2010;375(9718):924-937. PMID: 20226990